Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...3536373839404142434445...5960»
  • ||||||||||  Journal:  A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. (Pubmed Central) -  Jan 6, 2021   
    We believe that the present study will be the basis of future epidemiological investigations of pituitary surgery. Evidence-based approach consensus recommendations address important clinical issues regarding multidisciplinary management of acromegaly-related cardiovascular, endocrine, metabolic, and oncologic comorbidities, sleep apnea, and bone and joint disorders and their sequelae, as well as their effects on quality of life and mortality.
  • ||||||||||  Journal:  Acromegaly in the setting of Tatton-Brown-Rahman Syndrome. (Pubmed Central) -  Jan 6, 2021   
    Current clinical management for acromegaly is homogeneous across Spain and generally follows clinical guidelines. Our case suggests that TBRS might be associated with pituitary adenoma and a broader spectrum of tumors than previously thought, making long-term follow up of these patients crucial to identify tumors early, and to elucidate the clinical spectrum of the disorder for optimization of management.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Biomarker, Retrospective data, Journal:  Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. (Pubmed Central) -  Jan 6, 2021   
    P3
    Our case suggests that TBRS might be associated with pituitary adenoma and a broader spectrum of tumors than previously thought, making long-term follow up of these patients crucial to identify tumors early, and to elucidate the clinical spectrum of the disorder for optimization of management. The use of predictive factors at baseline and week 12 of treatment could inform clinical expectations of the long-term efficacy of lanreotide autogel.
  • ||||||||||  Journal:  Risk for acromegaly-related comorbidities by sex in Korean acromegaly. (Pubmed Central) -  Jan 6, 2021   
    Over the entire period, DM developed in 51.1% and 57.0% of male and female acromegalic patients, respectively. Mortality risk was higher (HR 1.65, 95% CI: 1.13-2.41) and statistically significant in females (HR 1.75, 95% CI: 1.07-2.84).
  • ||||||||||  Journal:  Acromegaly: Diabetes and HOMA-IR. (Pubmed Central) -  Dec 29, 2020   
    Tc-methylene diphosphonate bone scintigraphy revealed decreased uptake at the tumor site contrary to the usual finding of avid uptake by the neoplastic bone forming tumor. No abstract available
  • ||||||||||  Journal:  A rare complication: Infection in acromegalic renal cysts. (Pubmed Central) -  Dec 29, 2020   
    Renal cysts are detected in one third of acromegaly patients, especially in uncontrolled cases. Clinicians should pay attention to unexpected infection of enlarged renal cysts in acromegaly patients.
  • ||||||||||  [VIRTUAL] Evaluation of the Use of Octreotide in an Academic Medical Center () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_4735;    
    History of cirrhosis or variceal bleed, continuation of octreotide from home or outside facility, and indication for octreotide use will all be collected. Where applicable, specialty team consultation, presence or absence of bolus dosing, and discharge prescription details will be collected.
  • ||||||||||  Journal:  Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma. (Pubmed Central) -  Dec 17, 2020   
    There are several conditions that present with clinical aspects of acromegaly or gigantism but without growth hormone (GH) excess. Such cases are described as "pseudoacromegaly" or "acromegaloidism".In cases of excessive soft tissue growth with normal GH levels, other growth promotors (for example, thyroid hormone, sex hormones, insulin and others) should be taken into consideration.Biochemical confirmation of GH excess in patients presenting with clinical features of acromegaly and pituitary adenoma should always be considered to avoid unnecessary surgeries.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). (Pubmed Central) -  Dec 17, 2020   
    Such cases are described as "pseudoacromegaly" or "acromegaloidism".In cases of excessive soft tissue growth with normal GH levels, other growth promotors (for example, thyroid hormone, sex hormones, insulin and others) should be taken into consideration.Biochemical confirmation of GH excess in patients presenting with clinical features of acromegaly and pituitary adenoma should always be considered to avoid unnecessary surgeries. Nurses preferred the user experience of the LAN new syringe compared with the octreotide LAR syringe, with a particular preference for attributes related to product delivery with the LAN new syringe.
  • ||||||||||  Trial completion date, Trial primary completion date:  Acromegaly - Before and After Treatment (clinicaltrials.gov) -  Dec 7, 2020   
    P=N/A,  N=20, Recruiting, 
    When compared with the control group, we found that DTC patients with acromegaly did not have a worse evolution. Trial completion date: Nov 2021 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Dec 2022
  • ||||||||||  [VIRTUAL] Acromegaly (Porto Room) -  Dec 2, 2020 - Abstract #ENEA2020ENEA_138;    
  • ||||||||||  [VIRTUAL] TRENDS IN DISCORDANCE BETWEEN GH AND IGF-1 AFTER SUCCESSFUL PITUITARY SURGERY FOR ACROMEGALY () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_75;    
    Out of 28 patients with discordant IGF-1 / GH levels and no imaging tumor evidence at 3 months, only 15% presented biochemical and tumor recurrence, while the majority had no recurrence disease during follow-up. Therapeutic approach should be individualized between additional medical treatment and close follow-up in biochemically discordant patient.
  • ||||||||||  [VIRTUAL] HYPERTENSION AND METABOLIC COMORBIDITIES IN ACROMEGALY () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_44;    
    These findings are similar to other series and can be explained by long-term exposure to excess GH and IGF1 levels that may result in irreversible changes in different tissues. Effective management of acromegaly comorbidities is essential through specific treatment for each comorbidity.
  • ||||||||||  [VIRTUAL] CASE SERIES OF ACROMEGALY IN A SINGLE CENTER OVER SEVEN YEARS () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_35;    
    Acromegaly may still be underdiagnosed, in spite of better lab and imaging techniques. Surgical treatment is not always curative and complementary therapies, like radiotherapy and somatostatin analogues, are important to maintain normal lev- els of GH and IGF-1 and to prevent complications related to long standing non-controlled acromegaly.
  • ||||||||||  [VIRTUAL] T2-HYPOINTENSE VS NON T2- HYPOINTENSE PITUITARY ADENOMAS IN ACROMEGALY: BASELINE CHARACTERISTICS AND SHORT-TERM FOLLOW-UP () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_34;    
    T2-hypointense signal was associated with higher baseline IGF-1 levels and smaller and less invasive tumors, as previously described in the literature.1 However, it did not lead to higher prevalence of IGF-1 normalization at 1-year follow-up, showing that acromegaly treatment response is multifactorial and complex. nevertheless, we believe that the assessment of T2 sig- nal intensity at diagnosis is a relevant and easy method of cat- egorizing pituitary adenomas and potentially predict some of its characteristics.
  • ||||||||||  [VIRTUAL] MULTIPLE ENDOCRINE NEOPLASIA: A CASE SERIES OF 7 FAMILIES () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_19;    
    Rejection of a prophylactic surgery (case 5); Clinical diagnosis and surveillance after a negative genetic screen- ing (cases 6 and 7). We reviewed the literature and discuss the management of these patients.
  • ||||||||||  cabergoline / Generic mfg., epinephrine / Generic mfg.
    [VIRTUAL] A CASE OF FAMILIAL ACROMEGALY AND BILATERAL ASYNCHRONOUS PHEOCHROMOCYTOMAS DUE TO A MAX MUTATION () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_12;    
    The role of MAX in familial pheochromocytomas / paragan- gliomas has been investigated, although its role in development of familial pituitary adenomas remains to be established. Here we describe a female patient with familial acromegalegaly (PA, possibly of mixed GH / PRL secretion) and bilateral asynchronous pheochromocytomas with a nonsense MAX mutation.
  • ||||||||||  [VIRTUAL] GASTROINTESTINAL ADVERSE EVENTS WITH ORAL OCTREOTIDE CAPSULES: SAFETY RESULTS FROM THE PHASE 3 CHIASMA OPTIMAL STUDY () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_5;    
    GI AEs more prevalent in the placebo group including constipation, upper abdominal pain, and flatulence may have been disease related or related to the withdrawal of long-acting SRLs. Safety results from the CHIASMA OPTIMAL study indicate that GI AEs resolved on average within about a week, and AE frequency reduced with time, unlike GI AEs associated with long-acting SRLs, which tend to recur in patients for a few days after injection.3 with GI AEs being most commonly encountered.